Insights into the structural requirements of PKCβII inhibitors based on HQSAR and CoMSIA analyses

Area of Science:

• Medicinal Chemistry
• Computational Chemistry
• Pharmacology

Background:

• Diabetic cardiomyopathy is characterized by ventricular dysfunction in diabetic patients without atherosclerosis or hypertension.
• Selective inhibition of Protein Kinase C beta II (PKCβII) is a promising strategy for managing microvascular complications.
• Understanding structure-activity relationships is crucial for developing effective therapeutic agents.

Purpose of the Study:

• To identify key structural features of maleimide-based molecules that inhibit PKCβII.
• To develop reliable quantitative structure-activity relationship (QSAR) models for predicting PKCβII inhibitory activity.
• To guide the design of novel and more potent PKCβII inhibitors.

Main Methods:

• Employed 3D-Quantitative Structure-Activity Relationship (HQSAR) and Comparative Molecular Similarity Indices Analysis (CoMSIA) studies.
• Utilized a dataset of 43 maleimide-based molecules with known PKCβII inhibitory activity.
• Validated the predictive power and reliability of the developed QSAR models.

Main Results:

• Achieved high predictive accuracy with HQSAR (R²=0.98, Q²=0.85) and CoMSIA (R²=0.98, Q²=0.85) models.
• Identified that terminal electronegative atom substitution on indole or azaindole rings is essential for PKCβII inhibition.
• Determined that bulkier substitutions in the linker region decrease inhibitory activity.

Conclusions:

• The developed HQSAR and CoMSIA models provide reliable predictions for PKCβII inhibitory activity.
• Structural insights gained are valuable for the rational design of new maleimide-based PKCβII inhibitors.
• This research contributes to the development of novel therapeutic strategies for diseases associated with PKCβII dysregulation.